Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zidovudine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Filgrastim | DRUG | - |
| Epoetin alfa | DRUG | - |
| Zidovudine | DRUG | - |
Inclusion Criteria Concurrent Medication: Allowed: * Ganciclovir (DHPG) for treatment of CMV infections. Concurrent Treatment: Allowed: * Radiotherapy or laser therapy for Kaposi's sarcoma lesions provided dose does not exceed 3000 rads to any one lesion group and/or greater than 10 cm total b...
Top 20 of 28 competitors
Zidovudine is a small molecule being studied for the treatment of HIV Infections. It is currently in Phase 1 clinical development as an investigational drug. The drug is being evaluated in patients with HIV, including those with AIDS or severe AIDS-related complex.
Zidovudine is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. The company is conducting clinical research on this small molecule drug for the treatment of HIV Infections.
Zidovudine is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of HIV Infections, with one completed Phase 1 clinical trial.
Zidovudine has been studied in one clinical trial, NCT00002255, which was an open-label Phase I/II study. The trial evaluated recombinant granulocyte colony stimulating factor and recombinant erythropoietin given subcutaneously along with zidovudine in patients with AIDS or severe AIDS-related complex. The trial was completed in the United States.
Zidovudine is also known as AZT, as referenced in the clinical trial title for study NCT00002255. The drug is being developed by Amgen Inc. for the treatment of HIV Infections and is currently in Phase 1 clinical development.